Robust, Contrast-Free Functional Renal MRI

稳健、无对比的功能性肾脏 MRI

• 批准号: 10578551
• 负责人: ADAM M BUSH
• 金额: $ 54.22万
• 依托单位: UNIVERSITY OF TEXAS AT AUSTIN
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-05-01 至 2028-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10578551
• 关键词: 3-Dimensional; APOL1 gene; Abdomen; Adoption; Adult; Affect; African American; African American population; Agreement; American; Anemia; Biological Assay; Biological Markers; Black American; Blood; Blood Pressure; Blood flow; Bolus Infusion; Brain; Chronic Kidney Failure; Clinical; Clinical Trials; Collection; Complex; Consumption; Contrast Media; Creatinine; Development; Diabetes Mellitus; Diagnosis; Diet; Dimensions; Disease; Diuresis; Drug usage; Economic Factors; End stage renal failure; Environmental Pollution; Estimation Techniques; Evaluation; Filtration; Foundations; Functional Magnetic Resonance Imaging; Gadolinium; Gases; Genetic; Glomerular Filtration Rate; Glycosylated hemoglobin A; Goals; Healthcare; Image; Imaging Techniques; Individual; Inequity; Infusion procedures; Inhalation; Injections; Kidney; Kidney Diseases; Life Style; Link; Magnetic Resonance Imaging; Maps; Medical; Methods; Modality; Modeling; Motion; Near-Infrared Spectroscopy; Nitrogen; Operative Surgical Procedures; Organ; Outcome; Oxygen; Oxygen saturation measurement; Patients; Perfusion; Persons; Phase; Physics; Physiological; Plasma; Policies; Population Heterogeneity; Predisposition; Product Packaging; Protocols documentation; Race; Radial; Radiation; Renal Plasma Flow; Renal function; Research Methodology; Resolution; Rest; Risk; Safety; Scanning; Screening procedure; Serum; Sickle Cell Trait; Slice; Techniques; Testing; Time; Tissues; Toxic effect; Tubular formation; Underserved Population; Urine; Validation; Vendor; Water; Work; arterial spin labeling; bioaccumulation; blood oxygen level dependent; clinical imaging; data acquisition; data modeling; deoxyhemoglobin; hemodynamics; human old age (65+); image reconstruction; improved; indexing; kinetic model; magnetic resonance imaging biomarker; motion sensitivity; nephrotoxicity; next generation; novel; perfusion imaging; physiologic model; prevent; radiation risk; recruit; social factors; spatiotemporal; success; temporal measurement; tissue oxygenation

Chronic kidney disease (CKD) is a global problem affecting 500 million people worldwide. Glomerular filtration rate (GFR) is the clinical standard assay for the assessment of kidney function, however existing estimation techniques are imperfect. Gold-standard, accurate, collection based GFR techniques are time consuming, complex and rarely used, whereas cheap, effective GFR test like serum creatinine are often inaccurate. As a result, CKD, particularly subclinical CKD (Stage 1 and 2, GFR 60-100 ml/min) is grossly under-diagnosed and vastly understudied. Accurate identification of CKD is particularly important in Black Americans. Despite recent improvements in outcomes, CKD remains 15% more common, and end stage renal disease 3x more common in Black Americans as compared to non-Black Americans. Medical policy, genetics, economics and social factors have all been suggested as casual reasons for the observed inequities in renal outcomes. Unfortunately, until better screening tools of early renal disease are available, the exact determinants of CKD will be difficult to establish. Toward this end, we hypothesize that overcoming technical challenges related to motion sensitivity and physiological MR modeling will enable renal functional magnetic resonance imaging (rfMRI) to generate biomarkers that have superior safety, ease and accuracy as compared to existing GFR techniques The proposed aims will develop, validate and test two novel methods of GFR determination in Black Americans with a propensity for subclinical kidney disease. Aim 1: Develop and Validate Robust Oximetry and DeoxyHb Dynamic Susceptibly Contrast (dDSC) MRI. Aim 2: Develop and Validate Motion Robust, Blood Water, PROPELLER Renal Arterial Spin Labeling MRI. Aim 3: Evaluate Non-Contrast rfMRI in Adult African Americans with Subclinical Renal Disease. This proposal will consist of critical development and evaluation steps that will help characterize and facilitate the rapid and widespread adoption of non-ionizing, non-contrast hydro/hemodynamic biomarkers of renal function for a historically underserved population and all patients with kidney disease.

慢性肾病 (CKD) 是一个影响全球 5 亿人的全球性问题。肾小球滤过 肾小球滤过率（GFR）是评估肾功能的临床标准测定方法，但是现有的估计 技术不完善。黄金标准、准确、基于收集的 GFR 技术非常耗时， 复杂且很少使用，而廉价、有效的 GFR 测试（如血清肌酐）通常不准确。作为一个 结果，CKD，特别是亚临床 CKD（1 期和 2 期，GFR 60-100 ml/min）的诊断严重不足，并且 未被充分研究。 准确识别 CKD 对于美国黑人来说尤为重要。尽管最近有所改进 结果显示，美国黑人中 CKD 的常见率仍高出 15%，终末期肾病的常见率高出 3 倍 与非黑人美国人相比。医疗政策、遗传、经济和社会因素都已 建议作为观察到的肾脏结果不平等的偶然原因。不幸的是，直到更好的筛选 虽然早期肾脏疾病的工具已经可用，但 CKD 的确切决定因素将很难确定。 为此，我们假设克服与运动灵敏度和 生理 MR 建模将使肾功能磁共振成像 (rfMRI) 能够生成 与现有 GFR 技术相比，生物标志物具有卓越的安全性、简便性和准确性 拟议的目标将开发、验证和测试两种测定美国黑人 GFR 的新方法 有亚临床肾脏疾病的倾向。 目标 1：开发并验证稳健的血氧测定法和 DeoxyHb 动态敏感性对比 (dDSC) MRI。 目标 2：开发并验证运动鲁棒性、血水、PROPELLER 肾动脉旋转标记 MRI。 目标 3：评估患有亚临床肾病的成年非洲裔美国人的非对比 rfMRI。 该提案将包括关键的开发和评估步骤，这些步骤将有助于描述和促进 肾病的非电离、非对比水力/血流动力学生物标志物的快速和广泛采用 为历史上服务不足的人群和所有肾病患者提供服务。